← Back to Clinical Trials
Recruiting NCT05371886

NCT05371886 Pharmacokinetics-pharmacodynamics of Morphine With or Without Midazolam Administered by Continuous Infusion in Neonatal Intensive Care

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05371886
Status Recruiting
Phase
Sponsor Centre Hospitalier Intercommunal Creteil
Condition Sedation Complication
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2023-04-01
Primary Completion 2023-07-01

Eligibility & Interventions

Sex All sexes
Min Age 20 Weeks
Max Age 45 Weeks
Study Type INTERVENTIONAL
Interventions
Dose-effect relationship of morphine +/- midazolam administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2023-04-01 with a primary completion date of 2023-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to describe a dose-effect relationship of morphine alone and morphine and midazolam administered as continuous infusion in neonates hospitalized in Neonatal intensive care unit and undergoing mechanical ventilation, through PKPD modelling.

Eligibility Criteria

Inclusion Criteria: * Neonates \< 45 weeks of corrected gestational age * Hospitalized in a Neonatal Intensive Care Unit * Undergoing mechanical ventilation * Patients that receive morphine alone or morphine and midazolam as continuous infusion * Affiliated to a social security system Exclusion Criteria: * Current weight \< 600g * Neonates under palliative care * Therapeutic hypothermia for perinatal anoxia * Neonates who underwent a surgical procedure during the past 72 hours * Neonates receiving concomitantly a paralytic or another drug for sedation or analgesia other than morphine or midazolam (except for paracetamol/acetaminophen) * Parents refusing that their child participate

Contact & Investigator

Central Contact

Manon TAUZIN, MD

✉ manon.tauzin@chicreteil.fr

📞 01 45 17 50 00

Frequently Asked Questions

Who can join the NCT05371886 clinical trial?

This trial is open to participants of all sexes, aged 20 Weeks or older, up to 45 Weeks, studying Sedation Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05371886 currently recruiting?

Yes, NCT05371886 is actively recruiting participants. Contact the research team at manon.tauzin@chicreteil.fr for enrollment information.

Where is the NCT05371886 trial being conducted?

This trial is being conducted at Brest, France, Corbeil-Essonnes, France, Créteil, France, Lille, France and 1 additional location.

Who is sponsoring the NCT05371886 clinical trial?

NCT05371886 is sponsored by Centre Hospitalier Intercommunal Creteil. The trial plans to enroll 180 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology